All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub

Brought to you by Scientific Education Support

Scientific Education Support

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Kura Oncology, Syndax, Abbvie, Thermo Fisher and Johnson & Johnson. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My AML Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View AML content recommended for you

EHA 2023

Share:

Jun 8, 2023

X post image

12 Jun 2023

#EHA2023 | We hope you’ve enjoyed our daily coverage of the EHA 2023 Congress!

Keep an eye on our socials for post-congress content and key insights. 📲

#AML #cancerawareness #leukemia

X post image

11 Jun 2023

CONGRESS #EHA2023 | Amir Fathi @MassGeneralNews presents Ph 1 KOMET-001 study results showing ziftomenib was well tolerated in pts with R/R NPM1-m #AML. DS events were clinical manageable. CR was 35%; median DoR was 8.2 mo with MRD clearance of NPM1-m & key co-mutations.
#leusm

X post image

11 Jun 2023

Congress | #EHA2023 | Poster @MariaAmaya_27 @CUAnschutz presents results from a phase I trial of the all-oral CC-486 and venetoclax regimen in pts with R/R AML. Results demonstrate the safety and efficacy of this regimen, with pts successfully bridged to transplant. #leusm

X post image

11 Jun 2023

Congress | #EHA2023 | Poster @A_Stein_AHC @cityofhope presents preliminary safety and efficacy data of SAR443579 from a phase I/II trial in patients with R/R AML. SAR443579 was well tolerated up to doses of 3000µg/kg QW, with clinical benefit in patients with R/R AML. #leusm

X post image

11 Jun 2023

CONGRESS|#EHA2023 Marius Bill @Medizin_TUD discusses the prognostic value of the ELN2022 risk stratification in a large cohort. 21.7% of pts changed risk group vs ELN17 risk and reclassification showed improved prognostic discrimination for OS #AMLsm #leukemia #medicalcongress

X post image

11 Jun 2023

#EHA2023 | Mark Levis @JohnsHopkins presents ph3 MORPHO results of FLT3 inhibitor gilteritinib as post-HCT maintenance for FLT3-ITD #AML. Primary outcome of RFS was not met (HR=0.679; p=0.0518) however gilteritinib had more pronounced effect in pts with detectable MRD
#leusm

X post image

11 Jun 2023

CONGRESS|#EHA2023 Richard Schlenk @HeidelbergU presents the results from the QuANTUM-First trial evaluating allo-HCT in 1st complete remission + quizartinib. Pts on Quiz who underwent allo-HCT in CR1 had longer OS than pts on placebo #AMLsm #leukemia #leusm #medicalcongress

X post image

11 Jun 2023

Congress | #EHA2023 | Poster Shaun Fleming, @AlfredHealth summarizes the phase Ib OMNIVERSE trial. Results suggest that a maximum tolerated dose of oral azacytidine 300mg QD × 14d + venetoclax 400mg QD × 28d has a manageable safety profile in patients with R/R AML. #leusm

X post image

11 Jun 2023

Congress | #EHA2023 | Poster Agnieszka Wierzbowska, @umedlodz shares results from the PALG-AML1/2016 study. Results indicate that flow cytometry Day 14 BM assessment is an independent indicator of cCR and cCR MRD-neg, and may help the selection of pts for second induction. #leusm

X post image

11 Jun 2023

Congress | #EHA2023 | Poster Gail Roboz, @WeillCornell @WCMLeukemia summarizes a sub-analysis from the QUAZAR AML-001 trial. For pts with NPM1 mutated AML at diagnosis, serial NPM1mut monitoring is feasible. Post-IC MRD negativity was associated with improved outcomes. #leusm

X post image

11 Jun 2023

Congress | #EHA2023 | EHA-ISLH Laboratory Diagnosis Workshop
Robert Hasserjian, @MassGeneralNews provides an overview of the ICC for AML and MDS and a comparison with the WHO classification. They highlight that clinicians should be aware of both classifications. #leusm

X post image

11 Jun 2023

Congress | #EHA2023 | EHA-ISLH Laboratory Diagnosis Workshop
Michaela Fontenay, @univ_paris_cite, discusses the WHO classification of myeloid malignancies, with a particular focus on AML and MDS. The WHO classification is based on morphology, cytogenetics, and molecular features.

X post image

11 Jun 2023

What better way to finish off a weekend of inspiring and exciting presentations at #EHA2023 than with the late breaking abstract session. Many congratulations to all speakers! @EHA_Hematology #medicalcongress #leukemia #leusm

X post image

11 Jun 2023

Congress | #EHA2023 | SWG session
@Gossenkoppele @amsterdamumc provides an interesting discussion on the novel clinical and therapeutic aspects of the ELN 2022 recommendations. They highlight the need for international collaboration and innovative trial design. #leusm

X post image

11 Jun 2023

Congress | #EHA2023 | SWG session
A captivating presentation by Hartmut Döhner, @UniklinikUlm where they provide an overview of the ELN 2022 risk stratification, MRD, and the genetic landscape in older patients with AML treated with less intensive therapies. #leusm

X post image

11 Jun 2023

Congress | #EHA2023 | SWG session
Robert Hasserjian, @MassGeneralNews presents an interesting overview and discussion of the International Consensus Classification of AML. They highlight the similarities and differences between the ICC and WHO 2022 classifications. #leusm

X post image

10 Jun 2023

CONGRESS #EHA2023 | @PratzKW @PennCancer shares long term follow-up data from VIALE-A, suggesting venetoclax can positively impact health-related quality of life in elderly patients with #AML. #amlsm #medicalcongress

X post image

10 Jun 2023

Congress | #EHA2023 Sascha Haubner, @MSKCancerCenter discusses the differential target profiles and efficacy of ADCLEC.syn1 and CD33-CARs in humanized AML models. ADCLEC.syn1 eradicates CD33-CAR-refractory AML and minimizes antigen escape and on-target HSPC toxicity. #leusm

X post image

10 Jun 2023

CONGRESS| Not much room left in the plenary abstracts session at #EHA2023! Looking forward to the presentations on the best scoring abstracts from the whole congress #leukemia #leusm #medicalcongress

X post image

10 Jun 2023

Congress | #EHA2023 | Poster Madelyn Burkart, @NorthwesternMed shares a retrospective analysis evaluating the clinical activity of FLAG-IDA + venetoclax in pts with ND or R/R AML. Results indicate that FLAG-IDA + venetoclax is an effective regimen for pts with AML. #leusm

X post image

10 Jun 2023

Congress | #EHA2023 | Poster Nigel Russell, @GSTTnhs presents updated toxicity and an interim survival analysis from the NCRI AML19V2 trial. The addition of midostaurin to DAGO1 and DAGO2 was safe in pts with ND FLT3 mutated AML, with promising survival at this point. #leusm

X post image

10 Jun 2023

Congress | #EHA2023 | Poster @super_madl @UKL_Leipzig highlights a retrospective analysis of outcomes in pts with NPM1 mutated AML with MRD relapse following MRD negativity in CR1. Outcomes did not differ with regard to ELN2022 risk at diagnosis or prior allo-HSCT. #leusm

X post image

10 Jun 2023

Congress | #EHA2023 | Poster Katja Sockel, @Medizin_TUD presents results from a phase II DELTA trial investigating the safety and efficacy of HMA +/− eltrombopag in elderly pts with AML. The addition of eltrombopag did not improve outcomes in elderly pts with AML. #leums

X post image

10 Jun 2023

RT @MDS_Hub: Congress | #EHA2023 | Poster Kristin Koenig, @OhioStateMed highlights safety and preliminary efficacy data from a phase I stud…

X post image

10 Jun 2023

Congress | #EHA2023 | Poster Andrew Wei, @PeterMacCC @TheRMH summarizes a sub-analysis from the QUAZAR AML-001 trial. Post-IC therapy impacted the gene mutational landscape. Persistence of CH-associated mutations was observed at relapse in both arms. #leusm

X post image

10 Jun 2023

RT @ALL_Hub_: CONGRESS| #EHA2023 Congratulations to Prof Irene Roberts on being awarded the Jean Bernard lifetime achievement award for all…

X post image

9 Jun 2023

Congress | #EHA2023 Nigel Russell, @GSTTnhs highlights results from the NCRI AML19 trial. FLAG-Ida-GO improved OS and reduced the number of patients who were MRD+ vs DA-GO in patients with NPM1 mutated AML. The OS benefit was independent of FLT3 mutational and MRD status. #leusm

X post image

9 Jun 2023

Congress | #EHA2023 @HarryGillHKUMed @hkumed discusses a multicenter phase II study where an entirely oral AAA-based induction regimen in a risk-adapted strategy that minimized chemotherapy was effective and safe in patients with ND APL across all risk categories and ages. #leusm

X post image

9 Jun 2023

Congress | #EHA2023 Juan Miguel Bergua Burgues, Hospital San Pedro de Alcántara, presents updated results from a phase I/II trial assessing the safety & efficacy of triplet combinations of azacitidine or low-dose cytarabine with venetoclax & quizartinib in ND unfit pts with AML.

X post image

9 Jun 2023

Congress | #EHA2023 Steven Knapper, @cardiffuni highlights results from the NCRI AML18 trial. The sequential addition of quizartinib to intensive chemotherapy was well tolerated but did not improve survival in older patients with AML. #leusm

X post image

9 Jun 2023

Congress | #EHA2023 Pau Montesinos, @HospitalLaFe presents preliminary results from the phase II QUIWI trial. Results indicate that the addition of quizartinib to 3+7 may improve survival vs placebo in patients with newly diagnosed FLT3-ITD WT AML. #leusm

X post image

9 Jun 2023

RT @MDS_Hub: Congress | #EHA2023 | Poster Claudia Haferlach, @leukaemielabor proposes a classification system for #MDS and AML using geneti…

X post image

9 Jun 2023

Congress | #EHA2023 | Poster Eytan Stein, @MSKCancerCenter highlights the clinical and molecular characteristics of exceptional responders to ivosidenib in patients with R/R mIDH1 AML. Progressive reduction of mIDH1 in the BM was associated with a prolonged response. #leusm

X post image

9 Jun 2023

Congress | #EHA2023 | Poster @YannisMantz @MontefioreNYC @EinsteinMed shares initial results from a phase Ib study assessing the safety and tolerability of different venetoclax doses with daunorubicin + cytarabine followed by high-dose cytarabine in pts with ND AML. #leusm

X post image

9 Jun 2023

Congress | #EHA2023 | Poster Adolfo De La Fuente, @MDAnderson_ES presents results from the retrospective MDA-AML-2018-06 study. Midostaurin plus IC was associated with a CR rate of 83.4% and a 2-year OS rate of 65% in pts with FLT3-ITD mutated AML in a real-world setting. #leusm

X post image

9 Jun 2023

Congress | #EHA2023 | Poster @PratzKW @PennMedicine @PennCancer highlights an analysis of long-term outcomes post-allo-HSCT in older pts with AML treated with venetoclax + HMAs in a phase Ib trial and the phase III VIALE-A trial. Venetoclax + HMAs can be a bridge to allo-HSCT.

X post image

9 Jun 2023

Congress | #EHA2023 | Poster @GCC_Cortes @GACancerCenter presents a subset analysis from a phase II trial of olutasidenib. Patients with IDH1 mutated AML who were R/R to venetoclax-based regimens and received olutasidenib achieved durable remissions. #leusm

X post image

9 Jun 2023

Congress | #EHA2023 | SWG session
Juan Flores-Montero, Salamanca University Hospital, provides insights into the basic principles and clinical applications of next-generation-flow. They highlight the need for education and support to increase the use of NGF. #leusm

X post image

9 Jun 2023

RT @MPN_Hub: CONGRESS | #EHA2023 | @beth_psaila @MRC_WIMM discussed the complex interaction between pro-inflammatory cells in MPN & AML. In…

X post image

9 Jun 2023

Congress | #EHA2023 | SWG session
@YvanSaeys @VIBLifeSciences @ugent delivers an interesting talk on AI models to analyze flow-cytometric data. They explain how these models can improve diagnostics and highlight the need for standardization and large multi-center studies. #leusm

X post image

8 Jun 2023

📖 #EHA2023 | With all the exciting content being shared at EHA 2023, the @AML_Hub and our steering committee have provided a list of top abstracts to look out for in #AML.

Check it out 👉 https://t.co/ZNR7J5s4cC

#AML #leukemia

X post image

7 Jun 2023

🗣 #EHA2023 | 1 day to go!

The @AML_Hub will be covering @EHA_Hematology virtually and in person.

📅 June 8–11, 2023
📍 Frankfurt, Germany and online

Watch out for live updates!

#leukemia #cancerawareness

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2023 European Hematology Association

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Clinical trials in AML - match patients with relevant trials

Newsletter

Subscribe to get the best content delivered to your inbox